SUMO2
Small ubiquitin-related modifier 2
Also known as: SMT3B, SMT3H2, SUMO2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P61956
- Gene
- SUMO2
- Ensembl
- ENSG00000188612
- Chromosome
- 17
- Canonical length
- 95 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear bodies,Calyx,Connecting piece,Flagellar centriole
OverviewNCBI Gene
This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
95 residues, UniProt reviewed canonical sequence.
>P61956|SUMO2
1 MADEKPKEGV KTENNDHINL KVAGQDGSVV QFKIKRHTPL SKLMKAYCER QGLSMRQIRF
61 RFDGQPINET DTPAQLEMED EDTIDVFQQQ TGGVYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SUMO2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 288 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 288 nTPM
- ovary: 269 nTPM
- thymus: 253 nTPM
- esophagus: 223 nTPM
- bone marrow: 217 nTPM
- skeletal muscle: 215 nTPM
Single-cell type
- late spermatids: 394 nCPM
- late primary spermatocytes: 279 nCPM
- esophageal apical cells: 202 nCPM
- parietal cells: 157 nCPM
- oocytes: 147 nCPM
- early spermatids: 132 nCPM
Immune cell
- total PBMC: 853 nTPM
- basophil: 834 nTPM
- eosinophil: 784 nTPM
- T-reg: 704 nTPM
- plasmacytoid DC: 618 nTPM
- non-classical monocyte: 551 nTPM
Brain region
- cerebellum: 217 nTPM
- hypothalamus: 175 nTPM
- white matter: 167 nTPM
- cerebral cortex: 166 nTPM
- spinal cord: 163 nTPM
- basal ganglia: 158 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.45
- gnomAD pLI
- 0.87
- gnomAD missense Z
- 2.2
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- positive regulation of proteasomal ubiquitin-dependent protein catabolic process
- positive regulation of transcription by RNA polymerase II
- protein sumoylation
Molecular functions
- protein tag activity
- RNA binding
- SUMO transferase activity
- ubiquitin protein ligase binding
- ubiquitin-like protein ligase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SUMO2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SUMO2 as an antibody target. Whether an autoantibody or antibody against SUMO2 could matter depends on whether native SUMO2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SUMO2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SUMO2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...